Prospects and progress of Listeria-based cancer vaccines

References

• da Silva AJ, Zangirolami TC, Novo-Mansur MTM, et al. Live bacterial vaccine vectors: an overview. Braz J Microbiol. 2014;45(4):1117–1129.
   PubMed Web of Science ®Google Scholar
• Tangney M, Gahan CG. Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Ther. 2010;10(1):46–55.
   PubMed Web of Science ®Google Scholar
• Singh R, Wallecha A. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to Clinic. Hum Vaccin. 2011;7:497–505.
   PubMed Web of Science ®Google Scholar
• Zhao X, Li Z, Gu B, et al. Pathogenicity and immunogenicity of a vaccine strain of Listeria monocytogenes that relies on a suicide plasmid to supply an essential gene product. Infect Immun. 2005;73:5789–5798.
   PubMed Web of Science ®Google Scholar
• Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA. 2004;101:13832–13837.
   PubMed Web of Science ®Google Scholar
• Schoen C, Kolb-Mäurer A, Geginat G, et al. Bacterial delivery of functional messenger RNA to mammalian cells. Cell Microbiol. 2005;7:709–724.
   PubMed Web of Science ®Google Scholar
• Loeffler DI, Schoen CU, Goebel W, et al. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Infect Immun. 2006;74(7):3946–3957.
   PubMed Web of Science ®Google Scholar
• Sinnathamby G, Lauer P, Zerfass J, et al. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother. 2009;32(8):856–869.
   PubMed Web of Science ®Google Scholar
• Rothman J, Paterson Y. Live-attenuated Listeria-based immunotherapy. Expert Rev Vaccines. 2013;12(5):493–504.
   PubMed Web of Science ®Google Scholar
• Wu X, Ju X, Du L, et al. Production of bacterial ghosts from gram-positive pathogen Listeria monocytogenes. Foodborne Pathog Dis. 2017;14(1):1–7.
   PubMed Web of Science ®Google Scholar
• Singh R, Paterson Y. Listeria monocytogenes as a vector for tumor-associated antigens for cancer immunotherapy. Expert Rev Vaccines. 2006;5(4):541–552.
   PubMed Web of Science ®Google Scholar
• Wood LM, Paterson Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol. 2014;4:1–22.
   PubMed Web of Science ®Google Scholar
• Shahabi V, Maciag PC, Rivera S, et al. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs. 2010;1(4):235–243.
   PubMedGoogle Scholar
• Stritzker J, Pilgrim S, Szalay AA, et al. Prodrug converting enzyme gene delivery by L. monocytogenes. BMC Cancer. 2008;8:94.
   PubMed Web of Science ®Google Scholar
• Amer MH. Gene therapy for cancer: present status and future perspective. Amer Mol Cell Therapies. 2014;2:27.
   PubMedGoogle Scholar
• Tangney M, van Pijkeren JP, Gahan CGM. The use of Listeria monocytogenes as a DNA delivery vector for cancer gene therapy. Bioeng Bugs. 2010;1:284–287.
   PubMedGoogle Scholar
• van Pijkeren JP, Morrissey D, Monk IR, et al. A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther. 2010;21(4):405–416.
   PubMed Web of Science ®Google Scholar
• Kunda NK, Wafula D, Tram M, et al. A stable live bacterial vaccine. Eur J Pharm Biopharm. 2016;103:109–117.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Zahedifard F. Therapeutic live vaccines as a potential anticancer strategy. Int J Cancer. 2012;131(8):1733–1743.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Davoudi N, Agi E, et al. Comparison of HCV core and coreE1E2 virus-like particles generated by stably transfected Leishmania tarentolae for stimulation of Th1 immune responses in mice. Curr Drug Deliv. 2017;14:1–10.
   Google Scholar
• Nasiri V, Dalimi A, Ghaffarifar F, et al. Immunogenicity and efficacy of live L. tarentolae expressing KMP11-NTGP96-GFP fusion as a vaccine candidate against experimental Visceral Leishmaniasis caused by L. infantum. Iran J Parasitol. 2016;11(2):144–158.
   PubMed Web of Science ®Google Scholar
• Bolhassani A, Shirbaghaee Z, Agi E, et al. VLP production in Leishmania tarentolae: a novel expression system for purification and assembly of HPV16 L1. Protein Expr Purif. 2015;116:7–11.
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh S, Bolhassani A, Rafati S, et al. A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers. Drug Deliv. 2013;20(3–4):190–198.
   PubMed Web of Science ®Google Scholar
• Salehi M, Taheri T, Mohit E, et al. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model. Immunotherapy. 2012;4(11):1107–1120.
   PubMed Web of Science ®Google Scholar
• Singh M, Quispe-Tintaya W, Chandra D, et al. Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy. Br J Cancer. 2014;111:1945–1954.
   PubMed Web of Science ®Google Scholar
• Dowd GC, Bahey-El-Din M, Casey PG, et al. Listeria monocytogenes mutants defective in gallbladder replication represent safety-enhanced vaccine delivery platforms. Hum Vaccin Immunother. 2016;12(8):2059–2063.
   PubMed Web of Science ®Google Scholar
• Lin Q, Zhou M, Xu Z, et al. Construction of two Listeria ivanovii attenuated strains expressing Mycobacterium tuberculosis antigens for TB vaccine purposes. J Biotechnol. 2015;196–197:20–26.
   PubMed Web of Science ®Google Scholar
• Yin Y, Tian D, Jia Y, et al. Attenuated Listeria monocytogenes, a Mycobacterium tuberculosis ESAT-6 antigen expression and delivery vector for inducing an immune response. Res Microbiol. 2012;163(8):540–549.
   PubMed Web of Science ®Google Scholar
• Abi Abdallah DS, Pavinski Bitar A, Oliveira F, et al. A Listeria monocytogenes-based vaccine that secretes sand fly salivary protein LJM11 confers long-term protection against vector-transmitted Leishmania major. Infect Immun. 2014;82(7):2736–2745.
   PubMed Web of Science ®Google Scholar
• Sciaranghella G, Lakhashe S, Ayash-Rashkovsky M, et al. A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly. Vaccine. 2011;29(3):476–486.
   PubMed Web of Science ®Google Scholar
• Hamilton SE, Badovinac VP, Khanolkar A, et al. Listeriolysin O-deficient Listeria monocytogenes as a vaccine delivery vehicle: antigen-specific CD8 T cell priming and protective immunity. J Immunol. 2006;177(6):4012–4020.
   PubMed Web of Science ®Google Scholar
• Liu D. Listeria-based anti-infective vaccine strategies. Recent Pat Anti Infect Drug Discov. 2006;1(3):281–290.
   PubMedGoogle Scholar
• Liang ZZ, Sherrid AM, Wallecha A, et al. Listeria monocytogenes: a promising vehicle for neonatal vaccination. Hum Vaccin Immunother. 2014;10(4):1036–1046.
   PubMed Web of Science ®Google Scholar
• Wood LM, Guirnalda PD, Seavey MM, et al. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol Res. 2008;42:233–245.
   PubMed Web of Science ®Google Scholar
• Sewell DA, Shahabi V, Gunn GR, et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res. 2004b;64:8821–8825.
   PubMed Web of Science ®Google Scholar
• Rothman J, Wallecha A, Maciag PC, et al. The use of living Listeria monocytogenes as an active immunotherapy for the treatment of cancer. In: Chakrabarty FAM, eds. Emerging cancer therapy: microbial approaches and biotechnological tools. Hoboken, NJ: John Wiley &Sons, Inc.; 2009.
   Google Scholar
• Brockstedt DG, Bahjat KS, Giedlin MA, et al. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med. 2005;11:853–860.
   PubMed Web of Science ®Google Scholar
• Sleator RD, Watson D, Hill C, et al. The interaction between Listeria monocytogenes and the host gastrointestinal tract. Microbiology. 2009;155:2463–2475.
   PubMed Web of Science ®Google Scholar
• Brockstedt DG, Skoberne M, Yewdall A, et al. Killed but metabolically active recombinant Listeria monocytogenes as an antigen delivery and activation platform for human dendritic cell-based cancer immunotherapy. Blood. 2004;104:34–47.
   PubMed Web of Science ®Google Scholar
• Angelakopoulos H, Loock K, Sisul DM, et al. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect Immun. 2002;70:3592–3601.
   PubMed Web of Science ®Google Scholar
• De Azevedo MSP, Santos Rocha C, Pereira VB, et al. Prospective uses of recombinant Lactococcus lactis expressing both listeriolysin O and mutated internalin A from Listeria monocytogenes as a tool for DNA vaccination. Genet Mol Res. 2015;14(4):18485–18493.
   PubMed Web of Science ®Google Scholar
• Broeker NP. Listeria monocytogenes inlA/inlB as possible drug delivery systems. Faseb J. 2013;27(1):893.
   PubMed Web of Science ®Google Scholar
• Schoen C, Loeffler DI, Frentzen A, et al. Listeria monocytogenes as novel carrier system for the development of live vaccines. Int J Med Microbiol. 2008;298(1–2):45–58.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hou J, Lin Z, et al. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol. 2014;11:184–196.
   PubMed Web of Science ®Google Scholar
• Wallecha A, Wood L, Pan ZK, et al. Listeria monocytogenes-derived Listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability. Clin Vaccine Immunol. 2013;20(1):77–84.
   PubMed Web of Science ®Google Scholar
• Campillo-Navarro M, Leyva-Paredes K, Donis-Maturano L, et al. Listeria monocytogenes induces mast cell extracellular traps. Immunobiology. 2017;222(2):432–439.
   PubMed Web of Science ®Google Scholar
• Mirzaei R, Saei A, Torkashvand F, et al. Identification of proteins derived from Listeria monocytogenes inducing human dendritic cell maturation. Tumour Biol. 2016;37(8):10893–10907.
   PubMed Web of Science ®Google Scholar
• Hannan R, Zhang H, Wallecha A, et al. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer Immunol Immunother. 2012;61:2227–2238.
   PubMed Web of Science ®Google Scholar
• Zhou J. Advances and prospects in cancer immunotherapy. Hindawi Publishing Corporation; New Journal Science. 2014;2014:1–13.
   Google Scholar
• Paterson Y, Maciag PC. Listeria-based vaccines for cancer treatment. Curr Opin Mol Ther. 2005;7(5):454–460.
   PubMedGoogle Scholar
• Souders NC, Verch T, Paterson Y. In vivo bactofection: Listeria can function as a DNA-cancer vaccine. DNA Cell Biol. 2006;25(3):142–151.
   PubMed Web of Science ®Google Scholar
• Gunn GR, Peters C, Paterson Y. Listeriolysin-A useful cytolysin. Trends Microbiol. 2001;9:161–162.
   PubMed Web of Science ®Google Scholar
• Tilney LG, Portnoy DA. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J Cell Biol. 1989;109:1597–1608.
   PubMed Web of Science ®Google Scholar
• Peng X, Treml J, Paterson Y. Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy. Cancer Immunol Immunother. 2007;56:797–806.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ozbun L, Chong N, et al. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3- and CD8+ T cells. Cancer Immunol Res. 2014;2(9):911–922.
   PubMed Web of Science ®Google Scholar
• Mustafa W, Maciag PC, Pan ZK, et al. Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization. Viral Immunol. 2009;22(3):195–204.
   PubMed Web of Science ®Google Scholar
• Mkrtichyan M, Chong N, AbuEid RA, et al. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer. 2013;1:15.
   PubMedGoogle Scholar
• Skoberne M, Yewdall A, Bahjat KS, et al. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. J Clin Invest. 2008;118(12):3990–4001.
   PubMed Web of Science ®Google Scholar
• Calderon-Gonzalez R, Bronchalo-Vicente L, Freire J, et al. Exceptional anti-neoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma. Oncotarget. 2016;7(13):16855–16865.
   PubMed Web of Science ®Google Scholar
• Caisová V, Vieru A, Kumžáková Z, et al. Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model. BMC Cancer. 2016;16(1):940.
   PubMed Web of Science ®Google Scholar
• Campoli MR, Chang CC, Kageshita T, et al. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004;24:267–296.
   PubMed Web of Science ®Google Scholar
• Gravekamp C. The impact of aging on cancer vaccination. Curr Opin Immunol. 2011;23(4):555–560.
   PubMed Web of Science ®Google Scholar
• Lechner MG, Epstein AL. A new mechanism for blocking myeloid derived suppressor cells by CpG. Clin Cancer Res. 2011;17:1645–1648.
   PubMed Web of Science ®Google Scholar
• Maletto B, Ropolo A, Moron V, et al. CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/C mice. J Leukoc Biol. 2002;72:447–454.
   PubMed Web of Science ®Google Scholar
• Stacy S, Infante AJ, Wall K. Recall immune memory: a new tool for generating late onset autoimmune myasthenia gravis. Mech Ageing Dev. 2003;124:931–940.
   PubMed Web of Science ®Google Scholar
• Tan JT, Dudl E, LeRoy E. IL-7 is critical for homeostatic proliferation and survival of naïve T cells. PNAS. 2001;98:8732–8737.
   PubMed Web of Science ®Google Scholar
• Kim SH, Castro F, Paterson Y, et al. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res. 2009;69:5860–5866.
   PubMed Web of Science ®Google Scholar
• Kim SH, Castro F, Gonzalez D, et al. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer. 2008;99(5):741–749.
   PubMed Web of Science ®Google Scholar
• Bernhard H, Salazar L, Schiffman K, et al. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer. 2002;9:33–44.
   PubMed Web of Science ®Google Scholar
• Maciag P, Seavey M, Pan Z, et al. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008;68:8066–8075.
   PubMed Web of Science ®Google Scholar
• Shahabi V, Seavey MM, Maciag PC, et al. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther. 2010;18(1):1–10.
   PubMed Web of Science ®Google Scholar
• Wood LM, Pan ZK, Seavey MM, et al. The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother. 2012;61:689–700.
   PubMed Web of Science ®Google Scholar
• Ishizaki H, Song GY, Srivastava T, et al. Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother. 2010;33:609–617.
   PubMed Web of Science ®Google Scholar
• Mason NJ, Gnanandarajah JS, Engiles JB, et al. Immunotherapy with a HER2-targeting Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a Phase I trial in canine osteosarcoma. Clin Cancer Res. 2016;22(17):4380–4390.
   PubMed Web of Science ®Google Scholar
• Neeson P, Pan ZK, Paterson Y. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma. Cancer Immunol Immunother. 2008;57:493–505.
   PubMed Web of Science ®Google Scholar
• Chandra D, Selvanesan BC, Yuan Z, et al. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Oncotarget. 2017;8(13):20729–20740.
   PubMed Web of Science ®Google Scholar
• Shahabi V, Reyes-Reyes M, Wallecha A, et al. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother. 2008;57(9):1301–1313.
   PubMed Web of Science ®Google Scholar
• Wallecha A, Maciag PC, Rivera S, et al. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol. 2009;16(1):96–103.
   PubMed Web of Science ®Google Scholar
• Seavey MM, Maciag PC, Al-Rawi N, et al. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. J Immunol. 2009;182(9):5537–5546.
   PubMed Web of Science ®Google Scholar
• Wood LM, Pan ZK, Guirnalda P, et al. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol Immunother. 2011;60:931–942.
   PubMed Web of Science ®Google Scholar
• Quispe-Tintaya W, Chandra D, Jahangir A, et al. Non-toxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer. PNAS. 2013;110(21): 8668–8673.
   PubMed Web of Science ®Google Scholar
• Salman B, Zhou D, Jaffee EM, et al. Vaccine therapy for pancreatic cancer. OncoImmunology. 2013;2(12):e26662.
   PubMed Web of Science ®Google Scholar
• Wallecha A, Singh R, Malinina I. Listeria monocytogenes (Lm)-LLO Immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment. J Immunother. 2013;36:468–476.
   PubMed Web of Science ®Google Scholar
• Petit RG, Basu P. ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. J Immunother Cancer. 2013;1:P231.
   Google Scholar
• Cory L, Chu C. ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum Vaccin Immunother. 2014;10:3190–3195.
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33:1325–1333.
   PubMed Web of Science ®Google Scholar
• Gunn GR, Zubair A, Peters C, et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papillomavirus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167:6471–6479.
   PubMed Web of Science ®Google Scholar
• Sewell DA, Douven D, Pan ZK, et al. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg. 2004a;130:92–97.
   PubMed Web of Science ®Google Scholar
• Shahabi V, Seavey MM, Maciag PC, et al. Development of alive and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther. 2010;18:53–62.
   PubMed Web of Science ®Google Scholar
• Khan JA, Rathore RS, Khan S, et al. Role of Listeria monocytogenes in human health: disadvantages and advantages. Handb Microbial Bioresour. 2016;12:193–203.
   Google Scholar